Cyanamid v. Director of Patents
REITERATIONFacts
The Antecedents: Petitioner, American Cyanamid Company (Cyanamid), filed a petition to cancel the trademark registration of SULMETINE, issued to respondent Tiu Chian. Cyanamid claimed ownership of the trademark SULMET, used since 1946 in the United States and first used in the Philippines on May 25, 1950, for which it filed an application for registration on May 3, 1956. SULMET is a veterinary product used for various poultry and animal conditions. Cyanamid alleged that Tiu Chian's trademark SULMETINE, used for similar veterinary purposes, was confusingly similar to its own, causing unfair competition. Procedural History: The Director of Patents denied Cyanamid's petition for cancellation. The Director found substantial and striking differences between the labels of SULMET and SULMETINE, specifically regarding the scope of application (all domesticated animals vs. chicken and domesticated birds), the prominent display of the manufacturer's name (AMERICAN CYANAMID COMPANY vs. HENRY'S LABORATORIES PHILIPPINES), and the form of the product (drinking water solution vs. tablets). The Director also reasoned that the syllables 'SUL' and 'MET' were derived from common chemical compounds ('Sulfa' and 'methyl') and that the addition of 'INE' by Tiu Chian created a marked distinction. Furthermore, the Director found no material damage sustained by Cyanamid. The Petition: Cyanamid appealed the decision of the Director of Patents, raising five assigned errors, primarily focusing on the alleged priority of use, confusing similarity, fraud in obtaining registration, the necessity of proving damages, and the validity of delegating hearing authority.
Issue(s)
Whether the trademark SULMETINE is confusingly similar to the trademark SULMET. Whether petitioner had priority in the use of its trademark SULMET over respondent Tiu Chian's use of his trademark SULMETINE. Whether respondent Tiu Chian's certificate of registration for the trademark SULMETINE was obtained by fraud. Whether petitioner is legally obliged to prove damages as a condition precedent for cancellation. Whether the Director of Patents erred in delegating the authority to hear and receive evidence to a hearing officer.
Ruling
The Supreme Court affirmed the decision of the Director of Patents, denying the petition for cancellation of the trademark SULMETINE. The Court held that there was no confusing similarity between the trademarks SULMET and SULMETINE that would justify cancellation.
Ratio Decidendi
On the issue of confusing similarity between SULMET and SULMETINE: The Court held that there was no infringement of trademark that would justify the cancellation of respondent's registered trademark SULMETINE. An examination of the documentary evidence confirmed the findings of the Director of Patents that there were striking differences between the two labels, Exhibits B and C, which precluded the possibility of the purchasing public confusing one product with the other. These differences included the coloring scheme, pictorial representation, the printed matter on the label (specifically the form of the product as drinking water solution versus tablets), and the clear indication of the source of the product. The Court emphasized that for veterinary medicinal products, the source or manufacturer is a most important factor in the mind of the purchaser, and the labels clearly indicated distinct sources: American Cyanamid Company, New York, for SULMET, and Henry's Laboratories Philippines for SULMETINE. The Court distinguished this case from Lim Hoa v. Director of Patents by noting that the products here are medicinal and purchasers are expected to be more cautious, unlike in the case of food seasoning products where consumers might be guided by pictorial representations. The Court also cited Mead Johnson & Co. v. N.V.J. Van Dorp, Ltd. and Ethepa v. The Director of Patents to support the principle that even with similarities in spelling or sound, glaring and striking differences in the overall presentation of trademarks can prevent confusion. The Court reiterated that the syllables 'SUL' and 'MET' are derived from common chemical compounds and the addition of 'INE' by respondent was sufficient to distinguish the product. On the issue of priority of use: The Court stated that in view of the conclusion that there is no confusing similarity between the trademarks, the priority in the use of the mark SULMET by the petitioner would have no decisive effect in granting the petition for cancellation. The primary consideration remains whether the marks are confusingly similar. On the issue of fraud in obtaining registration: The Court held that the question of whether the registration was obtained by fraud becomes necessary and important only when there is a finding of similarity between the contesting trademarks. Since no such similarity was found, this issue was rendered moot. On the issue of proving damages: The Court stated that any error or mistake by the Director of Patents regarding the burden of proof for damages would not affect the decision, which was principally based on the finding of no confusing similarity between the trademarks. The Court reiterated that proof of fraud must be coupled with a showing of similarity and damage. On the issue of delegation of authority to a hearing officer: The Court affirmed that the Director of Patents has the administrative flexibility to delegate the power to hold a hearing to subordinates. This is a matter of practical administrative procedure and does not affect the jurisdiction of the Director to render the decision, provided that the judgment and discretion finally exercised are those of the officer authorized by law. The Court noted that petitioner participated throughout the proceedings before the Hearing Officer without raising any objection, thus waiving any procedural defect.
Main Doctrine
The mere addition of a syllable to a trademark, coupled with substantial differences in the presentation, labeling, and nature of the product, can be sufficient to distinguish it from a prior trademark, thereby precluding a finding of confusing similarity that would warrant cancellation.